|Report ID : RC-3157||Category : Pharmaceuticals||Published Date : 2018|
|Publisher : S-AND-P||Pages : 15||Format : PDF|
This IDC Perspective provides a picture of the various technological tools that can be adopted in various stages of the value chain by pharmaceutical companies as they go for digital transformation. The regional readiness for the transformational adoption has been confirmed by analyzing a set of regional countries on the government drive and data protection policy in place. Use cases were discussed to provide a better visualization of the emerging tools. As pharmaceutical leaders are busy strategizing their future, IDC's advice for technology buyers would be a good guidance."Pharmaceutical companies are facing two major challenges: first, to meet the "digital consumer" demand for faster, patient-centric, outcome-based medicines; and second, to attain these demands at reduced drug prices. The only way to tackle both challenges is to adopt digitalization or digital transformation across the value chain. This could well be achieved as pharmaceutical leaders take digital disruption as an opportunity and not as a risk," says Manoj Vallikkat, research manager, Healthcare Insights, IDC Asia/Pacific.
TABLE OF CONTENTS Product Code: AP44350318 Executive Snapshot Situation Overview Introduction APEJ Is Evolving Technological Adoption APEJ Countries - Readiness China Government Drive Data Protection India Government Drive Data Protection Australia Government Drive Data Protection South Korea Government Drive Data Protection Positive Drive Research and Development Manufacturing Distribution Commercials Supply Chain Management Use Cases Internet of Things Artificial Intelligence Blockchain 3D Printing Patient Data Platform Advice for the Technology Buyer Learn More Related Research Synopsis
Akasaka biz tower,
5-3-1 akasaka minato-ku,
13284 bluejacket street overland park,
KS 66213 United States